Clinically, CREBBP and EP300 variants are frequently reported in DLBCL patients, are often mutually exclusive, and contribute to disease relapse and inferior prognosis (Juskevicius et al., 2017). Here, EP300 is linked to diffuse large B-cell lymphoma.